Govt injects $3m into Diag-Nose and Human Health's AI respiratory platform
Make us a preferred source
Make us a preferred source on Google
The news: Australian biotechnology company Diag-Nose.io and health platform Human Health have secured $3 million in funding from the Australian Government's Cooperative Research Centres Projects (CRC-P) program to develop an AI-powered platform for respiratory disease treatment.
The numbers: The project, RhinoMAP, has a total value is $8.4 million, including partner cash and in-kind contributions.
The context: The project aims to transform how conditions like asthma, sinusitis, and chronic obstructive pulmonary disease are monitored and treated.
The platform uses protein biomarkers from nasal fluid samples combined with patient-reported data to monitor airway inflammation in real-time.
The initiative brings together expertise from multiple organisations including Monash University, Mater Research, ENT Clinic Melbourne, Manse Medical, and Invetech.
What they said: Diag-Nose.io CEO and co-founder Eldin Rostom: "Current respiratory tools only tell half the story".
"Our platform, RhinoMAP, is like a radar for the respiratory system. It reveals whether inflammation is escalating, stable, or resolving to help clinicians course-correct or stay the path with confidence, guided by the disease biology itself."
Human Health co-founder Georgia Vidler, said: "This is a rare and powerful convergence of science, technology, and government; sectors that too often operate in isolation. It's the shift Australia needs — Silicon Valley does this every day. It's about time we did too."
The source: Diag-Nose.io and Human Health media release
